Genmab (NASDAQ:GMAB) said it will discontinue further clinical development of acasunlimab, as the company sharpens its focus on the most value-creating opportunities in its late-stage portfolio amid an increasingly competitive landscape.
The Copenhagen-based biotechnology company, which trades on the Nasdaq under the ticker GMAB, said the decision followed a comprehensive strategic review.
While acasunlimab has shown an encouraging clinical profile to date, Genmab said it will reallocate resources to programs it believes offer the highest potential impact for patients and shareholders.
Genmab will instead prioritize several late-stage assets, including EPKINLY® (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S®), all of which are advancing through late-stage development and form the core of the company’s oncology strategy.
Genmab said the discontinuation of acasunlimab is consistent with its disciplined portfolio prioritization and capital allocation framework and will not affect its full-year 2025 financial guidance.